Ischemic Mitral RegurgitationSURVIVENCT04023058
Stress Echo for Ischemic Mitral Valve Surgery
A study testing Mitral surgery in people with Ischemic Mitral Regurgitation, run by Saint Petersburg State University, Russia at 1 site in Russia.
Trial summary
Comparison patients with CABG alone vs. CABG+mitral surgery with non-massive ischaemic mitral regurgitation (IMR) depending on stress echo data. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Ischemic Mitral Regurgitation
- What is being tested?
- Mitral surgery
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 400 participants
- Where
- 1 siteRussia
- Study dates
- 1 Jan 2020to 31 Dec 2027
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Ischemic MR, ERO≥0.2 cm2 and RV≥30 ml.
- Indication for CABG
Who cannot join
- Unwillingness to give informed consent and to enter a regular follow-up program.
- Contraindications for SE.
Trial locations and contacts
1 site in 1 country.
About this study
Comparison patients with CABG alone vs. CABG+mitral surgery with non-massive ischaemic mitral regurgitation (IMR) depending on stress echo data.
Read the detailed description
Chronic ischaemic mitral regurgitation (IMR) is a frequent complication of coronary artery disease (CAD), and is associated with a poor prognosis and outcome. The role of concomitant mitral valve surgery for IMR in patients undergoing coronary artery bypass grafting (CABG) remains controversial. After myocardial infarction IMR is associated with poor outcome and prognosis with double mortality rates, it reduces survival following surgical or percutaneous revascularization. However, there is no consensus on the cut-off value of IMR. The thresholds to define severe secondary mitral regurgitation are need to be evaluated with regards to their impact on prognosis after mitral valve intervention. The European guidelines is defined effective regurgitant orifice (ERO)-0.2 cm2 and regurgitant volume (RV)-30ml, as the threshold for severe IMR, because of severe prognosis of this group. Whereas American guidelines are defined it as ERO-0.4 cm2 and RV-60ml, as it was no evidence to impact intervention on the IMR with ERO-0.2 cm2 and RV-30ml. Partly it's explained by the dynamic nature of the secondary MR. About 30% of patients from the group with non-massive regurgitation at rest, have dramatically increasing it during exercise. However, some patient have not changes or decreasing IMR during exercise and, probably, they have not such a negative impact on the hemodynamic by IMR. The pervious comparative studies, that were the base for recommendations did not differ the patients with and without changes IMR during exercise. The current guidelines doesn't support the stress echo (SE) exams before operation for assessing necessity in mitral valve operation. It's due to lack of information that prove of influence for survival after surgery depending on IMR dynamic parameters.
IMR study hypothesis: Stress echocardiography data, including ERO, RV, pulmonary pressure (PA) pressure, beta-lines - B-lines, contractile reserve, could be indications for mitral valve intervention in patient with CAD and chronic secondary mitral regurgitation, undergoing CABG. The patients of the group with non-massive (ERO-0.2 cm2 and RV-30ml) IMR have positive effect by mitral surgery if they have increasing IMR during exercise test. The group with massive IMR (ERO≥0.4 cm2 and RV≥60 ml) will be better according clinic, echo, stress echo results in comparison with non-massive non-operated subgroup.
Aim: To assess the value of stress echo testing for ischemic mitral surgery indication in patients undergoing CABG.
Inclusion criteria for all projects are:
- Age > 18 years
- IMR, ERO≥0.2 cm2 and RV≥30 ml.
- Indication for CABG
Exclusion criteria for all projects are:
- Unwillingness to give informed consent and to enter a regular follow-up program.
- Contraindications for stress echo.
Methods and design:
- In a prospective multicenter international randomized study, we will recruit patients whom CABG is planned.
- Conventional transthoracic echo. Patients will include into two groups: Group 1 - "Non-massive IMR" - ERO-0.2-0.39 cm2, and RV-30-59ml. Group 2 - "Massive IMR" - ERO≥0.4 cm2 and RV≥60 ml.
- Randomization of Group 1 (surgery/non-surgery).
- Exercise stress echocardiography of all the patients (Group 1 and Group 2). regional wall motion abnormality (RWMA), ejection fraction (EF), end diastolic volume (EDV), end systolic volume (ESV), contractile reserve, B-lines, ERO, RV, PA pressure at rest and during stress.
- 1-year clinical outcomes
- 1-year transthoracic echo data.
- 1-year stress echocardiography data.
- 3-year clinical outcomes
- 3-year transthoracic echo data.
- 3-year stress echocardiography data. Primary end-points: death, myocardial infarction, new hospital readmission, heart transplant, ventricular assist device implantation, aborted sudden death, pulmonary oedema (MACE).
Secondary end-points: physical capacity (changes in Watts, minutes of stress echocardiography), EDV, left atrium volume, EF at rest and during SE, ERO, RV, PA pressure, B-lines, contractile reserve at rest and during exercise in comparison with pre-operative data.
Expected results. Group 1, CABG - subgroup, CABG+mitral surgery subgroup. It's expected the improvement of physical capacity (changes in Watts, minutes of stress echocardiography), EDV, left atrium volume, EF at rest and during SE, ERO, RV, PA pressure, B-lines, contractile reserve at rest and during exercise in comparison with pre-operative data in CABG+mitral surgery subgroup already in 1-year follow-up. It's expected the improvement of physical capacity (changes in Watts, minutes of stress echo), EDV, left atrium volume, EF at rest and during stress echo, ERO, RV, PA pressure, B-lines, contractile reserve at rest and during exercise in comparison with CABG-subgroup already in 1-year follow-up. It's expected that more pronounce changes will be in CABG+mitral surgery subgroup with previously increasing IMR. The worst results are expected in CABG-subgroup with previously increasing IMR during exercise. There will be clarified which parameters would be more correlate with the clinic improvement (contractile reserve, B-lines, ERO etc). We expected reduced MACE till 3 year in CABG+mitral surgery subgroup with increasing IMR in comparison with CABG-subgroup with increasing IMR.
Group 2, The group with massive IMR (ERO≥0.4 cm2 and RV≥60 ml) will be better according clinic, echo, stress echo results in comparison with CABG-subgroup with increasing IMR from group 1. There will be clarified which parameters would be more correlate with the clinic improvement (contractile reserve, B-lines, ERO etc).
- Conditions
- Ischemic Mitral Regurgitation
- Being tested
- Mitral surgery
- Keywords
- ischemic mitral regurgitation, mitral surgery, stress echo
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Mitral surgeryProcedure or surgery
Guidelines approved mitral surgery
| Study group | Role | What they receive |
|---|---|---|
| CABG/increasing MR | No intervention | non-massive IMR with increasing IMR during exercise - CABG only |
| CABG+mitral surgery (MS)/increasing MR | Experimental | non-massive IMR with increasing IMR during exercise - CABG+ mitral surgery Receives: Procedure: Mitral surgery |
| CABG/non-increasing MR | No intervention | non-massive IMR non-increasing IMR during exercise - CABG only |
| CABG+MS/non-increasing MR | Experimental | non-massive IMR non-increasing IMR - CABG+ mitral surgery Receives: Procedure: Mitral surgery |
| Control 1 | Other | massive IMR at rest without increasing during exercise - CABG+ mitral surgery Receives: Procedure: Mitral surgery |
| Control 2 | Other | massive IMR at rest with increasing during exercise - CABG+ mitral surgery Receives: Procedure: Mitral surgery |
What is being measured
The primary outcome is the main question the study is designed to answer.
myocardial infarction
myocardial infarction
Measured: during 3 year
all-cause death
all-cause death
Measured: during 3 year
new hospital readmission
new hospitalization
Measured: during 3 year from including
re-operation
percutaneous coronary intervention, coronary bypass surgery, heart transplant
Measured: during 3 year
cardiac death
cardiac death
Measured: during 3 year
Secondary outcomes (9)
physical capacity
Change in Watts during stress test
Measured: Change from Baseline of physical capacity in Watts at 12 months, at 3 years
end diastolic volume of left ventricle
Change in milliliters by echocardiography
Measured: Change from Baseline of end diastolic volume of left ventricle at 12 months, at 3 years
left atrium volume
Change in milliliters by echocardiography
Measured: Change from Baseline of left atrium volume at 12 months, at 3 years
ejection fraction at rest and during stress echo
Change in percent by echocardiography at rest and at the peak of exercise during stress test
Measured: Change from Baseline of ejection fraction at 12 months, at 3 years
effective regurgitant orifice
Change in centimeter square of mitral effective regurgitant orifice by echocardiography
Measured: Change from Baseline at 12 months, at 3 years
right ventricle size
Change in centimeter of right ventricle by echocardiography
Measured: Change from Baseline at 12 months, at 3 years
pulmonary artery pressure pressure
Change in mm Hg of pulmonary pressure by echocardiography
Measured: Change from Baseline at 12 months, at 3 years
B-lines
counts of B-lines during by stress echocardiography
Measured: Change from Baseline at 12 months, at 3 years
Contractile reserve
Change in contractile reserve by stress echocardiography
Measured: Change from Baseline at 12 months, at 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Jul 2019
- Study start1 Jan 2020
- Primary completion31 Dec 2024 (estimated)
- Study completion31 Dec 2027 (estimated)
Why it stopped: Slow recruitment
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Ischemic Mitral RegurgitationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 400 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Saint Petersburg State University, Russia
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Efremov Sergey, Saint Petersburg State University, Russia
- Investigators
- Dmitry Shmatov, MD, PhD, Principal investigator, Saint Petersburg State University, Russia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04023058
- Sponsor's protocol ID
- 2/2019
- Acronym
- SURVIVE
- Status last verified
- Oct 2022
- First submitted
- 30 Jun 2019
- Last updated
- 20 Oct 2022
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Study Protocol, Clinical study report
Study at a glance
From the registry record, last updated by the sponsor on 20 Oct 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Stress Echo for Ischemic Mitral Valve Surgery
- ClinicalTrials.gov ID
- NCT04023058
- Acronym / sponsor ID
- SURVIVE / 2/2019
- Conditions
- Ischemic Mitral Regurgitation
- Keywords
- ischemic mitral regurgitation, mitral surgery, stress echo
- Study type
- Interventional
- Recruitment status
- SuspendedReason stopped: Slow recruitment
- Enrolment
- 400 participants (estimated)
- Lead sponsor
- Saint Petersburg State University, RussiaUniversity, hospital or other
- Study start
- 1 Jan 2020 (actual)
- Primary completion
- 31 Dec 2024 (estimated)
- Study completion
- 31 Dec 2027 (estimated)
- First posted
- 17 Jul 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Comparison patients with CABG alone vs. CABG+mitral surgery with non-massive ischaemic mitral regurgitation (IMR) depending on stress echo data.
Detailed description
Chronic ischaemic mitral regurgitation (IMR) is a frequent complication of coronary artery disease (CAD), and is associated with a poor prognosis and outcome. The role of concomitant mitral valve surgery for IMR in patients undergoing coronary artery bypass grafting (CABG) remains controversial. After myocardial infarction IMR is associated with poor outcome and prognosis with double mortality rates, it reduces survival following surgical or percutaneous revascularization. However, there is no consensus on the cut-off value of IMR. The thresholds to define severe secondary mitral regurgitation are need to be evaluated with regards to their impact on prognosis after mitral valve intervention. The European guidelines is defined effective regurgitant orifice (ERO)-0.2 cm2 and regurgitant volume (RV)-30ml, as the threshold for severe IMR, because of severe prognosis of this group. Whereas American guidelines are defined it as ERO-0.4 cm2 and RV-60ml, as it was no evidence to impact intervention on the IMR with ERO-0.2 cm2 and RV-30ml. Partly it's explained by the dynamic nature of the secondary MR. About 30% of patients from the group with non-massive regurgitation at rest, have dramatically increasing it during exercise. However, some patient have not changes or decreasing IMR during exercise and, probably, they have not such a negative impact on the hemodynamic by IMR. The pervious comparative studies, that were the base for recommendations did not differ the patients with and without changes IMR during exercise. The current guidelines doesn't support the stress echo (SE) exams before operation for assessing necessity in mitral valve operation. It's due to lack of information that prove of influence for survival after surgery depending on IMR dynamic parameters.
IMR study hypothesis: Stress echocardiography data, including ERO, RV, pulmonary pressure (PA) pressure, beta-lines - B-lines, contractile reserve, could be indications for mitral valve intervention in patient with CAD and chronic secondary mitral regurgitation, undergoing CABG. The patients of the group with non-massive (ERO-0.2 cm2 and RV-30ml) IMR have positive effect by mitral surgery if they have increasing IMR during exercise test. The group with massive IMR (ERO≥0.4 cm2 and RV≥60 ml) will be better according clinic, echo, stress echo results in comparison with non-massive non-operated subgroup.
Aim: To assess the value of stress echo testing for ischemic mitral surgery indication in patients undergoing CABG.
Inclusion criteria for all projects are:
- Age > 18 years
- IMR, ERO≥0.2 cm2 and RV≥30 ml.
- Indication for CABG
Exclusion criteria for all projects are:
- Unwillingness to give informed consent and to enter a regular follow-up program.
- Contraindications for stress echo.
Methods and design:
- In a prospective multicenter international randomized study, we will recruit patients whom CABG is planned.
- Conventional transthoracic echo. Patients will include into two groups: Group 1 - "Non-massive IMR" - ERO-0.2-0.39 cm2, and RV-30-59ml. Group 2 - "Massive IMR" - ERO≥0.4 cm2 and RV≥60 ml.
- Randomization of Group 1 (surgery/non-surgery).
- Exercise stress echocardiography of all the patients (Group 1 and Group 2). regional wall motion abnormality (RWMA), ejection fraction (EF), end diastolic volume (EDV), end systolic volume (ESV), contractile reserve, B-lines, ERO, RV, PA pressure at rest and during stress.
- 1-year clinical outcomes
- 1-year transthoracic echo data.
- 1-year stress echocardiography data.
- 3-year clinical outcomes
- 3-year transthoracic echo data.
- 3-year stress echocardiography data. Primary end-points: death, myocardial infarction, new hospital readmission, heart transplant, ventricular assist device implantation, aborted sudden death, pulmonary oedema (MACE).
Secondary end-points: physical capacity (changes in Watts, minutes of stress echocardiography), EDV, left atrium volume, EF at rest and during SE, ERO, RV, PA pressure, B-lines, contractile reserve at rest and during exercise in comparison with pre-operative data.
Expected results. Group 1, CABG - subgroup, CABG+mitral surgery subgroup. It's expected the improvement of physical capacity (changes in Watts, minutes of stress echocardiography), EDV, left atrium volume, EF at rest and during SE, ERO, RV, PA pressure, B-lines, contractile reserve at rest and during exercise in comparison with pre-operative data in CABG+mitral surgery subgroup already in 1-year follow-up. It's expected the improvement of physical capacity (changes in Watts, minutes of stress echo), EDV, left atrium volume, EF at rest and during stress echo, ERO, RV, PA pressure, B-lines, contractile reserve at rest and during exercise in comparison with CABG-subgroup already in 1-year follow-up. It's expected that more pronounce changes will be in CABG+mitral surgery subgroup with previously increasing IMR. The worst results are expected in CABG-subgroup with previously increasing IMR during exercise. There will be clarified which parameters would be more correlate with the clinic improvement (contractile reserve, B-lines, ERO etc). We expected reduced MACE till 3 year in CABG+mitral surgery subgroup with increasing IMR in comparison with CABG-subgroup with increasing IMR.
Group 2, The group with massive IMR (ERO≥0.4 cm2 and RV≥60 ml) will be better according clinic, echo, stress echo results in comparison with CABG-subgroup with increasing IMR from group 1. There will be clarified which parameters would be more correlate with the clinic improvement (contractile reserve, B-lines, ERO etc).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 6
| Arm | Type | Receives |
|---|---|---|
| CABG/increasing MR | No intervention | –non-massive IMR with increasing IMR during exercise - CABG only |
| CABG+mitral surgery (MS)/increasing MR | Experimental | Procedure: Mitral surgerynon-massive IMR with increasing IMR during exercise - CABG+ mitral surgery |
| CABG/non-increasing MR | No intervention | –non-massive IMR non-increasing IMR during exercise - CABG only |
| CABG+MS/non-increasing MR | Experimental | Procedure: Mitral surgerynon-massive IMR non-increasing IMR - CABG+ mitral surgery |
| Control 1 | Other | Procedure: Mitral surgerymassive IMR at rest without increasing during exercise - CABG+ mitral surgery |
| Control 2 | Other | Procedure: Mitral surgerymassive IMR at rest with increasing during exercise - CABG+ mitral surgery |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Ischemic MR, ERO≥0.2 cm2 and RV≥30 ml.
- Indication for CABG
Key exclusion criteria (2 listed)
- Unwillingness to give informed consent and to enter a regular follow-up program.
- Contraindications for SE.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Mitral surgeryGuidelines approved mitral surgery | Procedure or surgery | CABG+MS/non-increasing MR, CABG+mitral surgery (MS)/increasing MR, Control 1, Control 2 |
Primary outcome
myocardial infarction
Time frame: during 3 year
myocardial infarction
all-cause death
Time frame: during 3 year
all-cause death
new hospital readmission
Time frame: during 3 year from including
new hospitalization
re-operation
Time frame: during 3 year
percutaneous coronary intervention, coronary bypass surgery, heart transplant
cardiac death
Time frame: during 3 year
cardiac death
9 secondary outcomes
physical capacity
Time frame: Change from Baseline of physical capacity in Watts at 12 months, at 3 years
end diastolic volume of left ventricle
Time frame: Change from Baseline of end diastolic volume of left ventricle at 12 months, at 3 years
left atrium volume
Time frame: Change from Baseline of left atrium volume at 12 months, at 3 years
ejection fraction at rest and during stress echo
Time frame: Change from Baseline of ejection fraction at 12 months, at 3 years
effective regurgitant orifice
Time frame: Change from Baseline at 12 months, at 3 years
right ventricle size
Time frame: Change from Baseline at 12 months, at 3 years
pulmonary artery pressure pressure
Time frame: Change from Baseline at 12 months, at 3 years
B-lines
Time frame: Change from Baseline at 12 months, at 3 years
Contractile reserve
Time frame: Change from Baseline at 12 months, at 3 years
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Oct 2022.
- Individual participant dataSharing planned: Yes. Study Protocol, Clinical study report
Related trials for Ischemic Mitral Regurgitation
RecruitingObservational study
Continuous Dual Aspiration Technique With Zoom System for Stroke
Ischemic Stroke, Acute Stroke
Recruiting
Early Doppler-Assisted Mobilization in Adults After Acute Ischemic Stroke
Arterial Ischemic Stroke
Not yet recruitingObservational study
Impact of Stroke Unit Care on Acute Stroke Outcomes
Acute Stroke, Ischemic Stroke
Recruiting
Transcatheter Mitral Valve Repair for Inotrope Dependent Cardiogenic Shock
Cardiogenic Shock, Mitral Regurgitation
Active, not recruiting
REvascularization and Valve Intervention for Ischemic Valve diseasE: REVIVE Trial
Mitral Valve Insufficiency, Coronary Artery Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Dmitry Shmatov, MD, PhD principal investigator
Saint Petersburg State University, Russia
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Mitral surgery in people with Ischemic Mitral Regurgitation, run by Saint Petersburg State University, Russia at 1 site in Russia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: paused, as of the sponsor's last update on 20 Oct 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Russia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
myocardial infarction (time frame: during 3 year). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Oct 2022.